Mycoses is an indication for drug development with over 160 pipeline drugs currently active. According to GlobalData, preregistered drugs for Mycoses have a 94.74% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Mycoses compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mycoses overview
Mycoses, also known as fungal infections, encompass a diverse group of diseases caused by fungi. These infections can affect various tissues in the body, including the skin, nails, and internal organs. Superficial mycoses, like athlete’s foot and ringworm, involve the outer layers, while systemic mycoses can affect deeper tissues and may be more severe, particularly in individuals with weakened immune systems. Candidiasis is another common example, involving the overgrowth of the Candida yeast. Antifungal medications, both topical and systemic, are used for treatment. Prevention involves good hygiene practices and managing underlying conditions that may compromise the immune system.
For a complete picture of PTSR and LoA scores for drugs in Mycoses, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
